Clinical Trial Update: Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting on immunogenicity, safety and tolerability of two doses of adjuvanted and non-adjuvanted swine-origin A/H1N1 monovalent influenza…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pandemic Influenza

Drugs mentioned

• Focetria (A/H1N1 swine-origin influenza vaccine, monovalent)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pandemic Influenza | Phase 3 | Status: COMPLETED